August 4th 2020
Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.
Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.
Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.
August 3rd 2020
Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.
July 28th 2020
Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.
July 24th 2020
Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.
July 23rd 2020
Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.
Daniel H. Ahn, DO, discusses updated findings from the phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.
July 17th 2020
Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.
Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.
